Compare · CNC vs DGX
CNC vs DGX
Side-by-side comparison of Centene Corporation (CNC) and Quest Diagnostics Incorporated (DGX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CNC and DGX operate in Medical Specialities (Health Care), so they compete in similar markets.
- CNC is the larger of the two at $33.72B, about 1.5x DGX ($22.95B).
- Over the past year, CNC is up 123.0% and DGX is up 22.5% - CNC leads by 100.5 points.
- CNC has been more active in the news (12 items in the past 4 weeks vs 4 for DGX).
- Both have 25 recent analyst ratings on file.
- Company
- Centene Corporation
- Quest Diagnostics Incorporated
- Price
- $68.31+0.04%
- $206.37-0.45%
- Market cap
- $33.72B
- $22.95B
- 1M return
- +7.50%
- +1.23%
- 1Y return
- +123.03%
- +22.53%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 12
- 4
- Recent ratings
- 25
- 25
Centene Corporation
Centene Corporation operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. Its Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which cover dually eligible individuals, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray, home-based primary care, transportation assistance, vision care, dental care, telehealth, immunization, specialty pharmacy, therapy, social work, nurse advisory, and care coordination services, as well as prescriptions and limited over-the-counter drugs, medical equipment, and behavioral health and abuse services. This segment also offers various individual, small group, and large group commercial healthcare products to employers and directly to members in the Managed Care segment. The company's Specialty Services segment provides pharmacy benefits management services; nurse advice line and after-hours support services; and vision and dental services, as well as staffing services to correctional systems and other government agencies; and services to Military Health System eligible beneficiaries. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.
Quest Diagnostics Incorporated
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Latest CNC
- CENTENE CORPORATION TO HOST 2026 SECOND QUARTER FINANCIAL RESULTS EARNINGS CALL
- CENTENE SUBSIDIARY MERIDIAN HEALTH PLAN OF ILLINOIS AWARDED ILLINOIS MEDICAID CONTRACT
- Director Tyler Lauren M was granted 61 shares (SEC Form 4)
- Director Samuels Theodore R. Ii was granted 465 shares, increasing direct ownership by 2% to 25,213 units (SEC Form 4)
- Director Tanji Kenneth was granted 581 shares, increasing direct ownership by 5% to 12,490 units (SEC Form 4)
- Director Eppinger Frederick H was granted 833 shares, increasing direct ownership by 0.23% to 369,538 units (SEC Form 4)
- Director Coughlin Christopher J was granted 562 shares, increasing direct ownership by 3% to 18,711 units (SEC Form 4)
- Health Net Providing Special Assistance to Members and Providers Affected by Palos Warehouse Fire in Los Angeles
- RBC Capital Mkts initiated coverage on Centene with a new price target
- CENTENE APPOINTS LAUREN M. TYLER TO BOARD OF DIRECTORS
Latest DGX
- One in Five American Workers Tested Had a Positive Hair Drug Test in 2025, Signaling Persistent Long-Term Substance Use Patterns
- Quest Diagnostics Now the Largest Clinical Reference Lab to Extend Oncology Test Access Through OncoEMR MPI
- SEC Form 4 filed by Director Wentworth Timothy C
- Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing
- SEC Form 11-K filed by Quest Diagnostics Incorporated
- UTI-causing Bacteria Resistant to Current Drugs, Finds National Study by Hackensack Meridian CDI and Quest Diagnostics
- Quest Diagnostics to Release Second Quarter Financial Results on July 23, 2026
- Quest Diagnostics Unveils Achievements in Healthcare Access, Employee Engagement and Environmental Sustainability in 2025 Corporate Responsibility Report
- SVP, Clinical Solutions Kuppusamy Karthik exercised 8,147 shares at a strike of $124.22 and sold $1,629,400 worth of shares (8,147 units at $200.00) as part of a pre-agreed trading plan (SEC Form 4)
- CEO and President Davis J. E. sold $1,941,400 worth of shares (10,000 units at $194.14) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 132,423 units (SEC Form 4)